Dr. Li Wu is an attorney at law and patent attorney qualified to practice in both China and the United States. He provides services in all aspects of intellectual property law. On the one hand, he focuses on providing full spectrum of patent services including prosecution, re-examination, invalidation, and litigation, especially in the fields of biotechnology, pharmaceutical, chemical engineering and medical device. On the other hand, he also advises clients on matters in relation to trademark, copyright, trade secret, unfair competition and other IP related fields.
Prior to joining Anjie law firm, Dr. Wu had served in leading firms in both China and the United States. In addition, he also had experience in serving as in-house counsel for a multinational pharmaceutical company in China.
Before starting his legal career, Dr. Wu had worked as a scientist in the field of neuroscience for more than 10 years, and his work on the regulation of calcium channels has been published in the world famous scientific magazine Nature (Vol. 419:947-952).
Represented AstraZeneca in defending one of its core pharmaceutical compound patent before the courts and successfully overturned the invalidation decision made by the Patent Re-examination Board;
Represented Japanese company Nichia Corporation in a series of patent litigations against a Taiwan company Everlight Electronic before the Beijing IP Court and the Patent Re-examination Board, which are part of a global patent war between these two LED giants in the world;
Represented a leading auto parts company in a patent litigation concerning a cylinder liner patent before the Beijing IP court and the Patent Re-examination Board and won a completed victory for the client;
Represented Sinopec in a series of trade secret and patent disputes that claimed damages over one billion RMB in total and successfully helped the client achieve a settlement;
Represented a Japanese pharmaceutical company in patent infringement matter concerning a pharmaceutical process patent, the case went through trial and appeal and finally to retrial at the Supreme People’s Court and involved a damage award over RMB 5,000,000;
Represents a US communication company in patent invalidation matter concerning a 4G technology patent and won a completed victory for the to keep all patent claims valid;
Represented a Chinese public company in a 337 investigation before the ITC concerning CoQ10 and its usage.
Represent or represented high tech start-ups, public companies, multinational giants, as well as research institutions, such as Sinopec, Toyota, NEC, Yazaki, Novartis, Nihon Kohden, Align Technology, Nichia, Michigan University, UCSF, UCLA, Chinese Academy of Science, Qinghua University, Nanjing University, etc. in patent prosecution related matters concerning chemical engineering, autos, electrical engineering, pharmaceuticals, life sciences and medical devices, and successfully obtained and protected hundreds of patents in these fields;
“Data supplementation for chemical and biotech patents in China”, Chinese Business Law Journal, June 2018
"China to establish its own drug patent linkage", Chinese Business Law Journal, November 2017
"Coming to terms with the US introduction of DTSA", Chinese Business Law Journal, October, 2016
"Particularities of China's Biotechnology Patent Protection Regime", Chinese Business Law Journal, October, 2015
"Fourth amendment to Patent Law aims to increase damages and more", Chinese Business Law Journal, May, 2015
"SIPO Clarifies Its Sufficient Disclosure Requirement", Managing IP, February 2014
"Foreign enterprises should study China’s utility model patent regime", Chinese Business Law Journal, December, 2013
"DNA patentability in China", Symposium of the SIPO/US Bar Liaison Council with China's State Intellectual Property Office (SIPO) and the All China Patent Attorney Association (ACPAA), June 3, 2013 at Cardozo School of Law, New York, USA.